User login
Key clinical point: Cutaneous allodynia and aura contribute significantly to the risk for calcitonin gene-related peptide (CGRP)-induced migraine attacks in patients having migraine with or without aura.
Major finding: Overall, 79% of patients had CGRP-induced migraine attacks during a 12-hour observation period following CGRP infusion. The presence of cutaneous allodynia and aura, respectively, led to significant increase (odds ratio [OR] 3.26; P = .013) and decrease (OR 0.32; P = .02) in the risk for CGRP-induced migraine attacks.
Study details: The data come from a non-randomized, open-label trial including 139 patients having migraine with or without aura who received a continuous 20-min intravenous infusion of CGRP (dosage, 1.5 mg/minute).
Disclosures: This study was funded by a professor grant from the Lundbeck Foundation, Denmark. Five authors declared receiving personal fees and institutional grants from various sources. M Ashina declared serving as an associate editor of Cephalalgia, The Journal of Headache and Pain, and Brain.
Source: Al-Khazali HM et al. An exploratory analysis of clinical and sociodemographic factors in CGRP-induced migraine attacks: A REFORM study. Cephalalgia. 2023 (Oct 10). doi: 10.1177/03331024231206375
Key clinical point: Cutaneous allodynia and aura contribute significantly to the risk for calcitonin gene-related peptide (CGRP)-induced migraine attacks in patients having migraine with or without aura.
Major finding: Overall, 79% of patients had CGRP-induced migraine attacks during a 12-hour observation period following CGRP infusion. The presence of cutaneous allodynia and aura, respectively, led to significant increase (odds ratio [OR] 3.26; P = .013) and decrease (OR 0.32; P = .02) in the risk for CGRP-induced migraine attacks.
Study details: The data come from a non-randomized, open-label trial including 139 patients having migraine with or without aura who received a continuous 20-min intravenous infusion of CGRP (dosage, 1.5 mg/minute).
Disclosures: This study was funded by a professor grant from the Lundbeck Foundation, Denmark. Five authors declared receiving personal fees and institutional grants from various sources. M Ashina declared serving as an associate editor of Cephalalgia, The Journal of Headache and Pain, and Brain.
Source: Al-Khazali HM et al. An exploratory analysis of clinical and sociodemographic factors in CGRP-induced migraine attacks: A REFORM study. Cephalalgia. 2023 (Oct 10). doi: 10.1177/03331024231206375
Key clinical point: Cutaneous allodynia and aura contribute significantly to the risk for calcitonin gene-related peptide (CGRP)-induced migraine attacks in patients having migraine with or without aura.
Major finding: Overall, 79% of patients had CGRP-induced migraine attacks during a 12-hour observation period following CGRP infusion. The presence of cutaneous allodynia and aura, respectively, led to significant increase (odds ratio [OR] 3.26; P = .013) and decrease (OR 0.32; P = .02) in the risk for CGRP-induced migraine attacks.
Study details: The data come from a non-randomized, open-label trial including 139 patients having migraine with or without aura who received a continuous 20-min intravenous infusion of CGRP (dosage, 1.5 mg/minute).
Disclosures: This study was funded by a professor grant from the Lundbeck Foundation, Denmark. Five authors declared receiving personal fees and institutional grants from various sources. M Ashina declared serving as an associate editor of Cephalalgia, The Journal of Headache and Pain, and Brain.
Source: Al-Khazali HM et al. An exploratory analysis of clinical and sociodemographic factors in CGRP-induced migraine attacks: A REFORM study. Cephalalgia. 2023 (Oct 10). doi: 10.1177/03331024231206375